Slide 1: ASX Announcement: Investor Presentation
ASX ANNOUNCEMENT INVESTOR PRESENTATION For personal use only MELBOURNE (AUSTRALIA) 27 June 2022: Invion Limited (ASX: IVX) (“Invion” or the “Company”) wishes to release the attached presentation, which will be used in upcoming meetings with various brokers and investor groups. This announcement was
Slide 2: Investor Presentation June 2022
For personal use only INVESTOR PRESENTATION June 2022
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Company Overview: Developing the Next-Gen Photodynamic Therapy
COMPANY OVERVIEW DEVELOPING THE NEXT-GEN PHOTODYNAMIC THERAPY (PDT) For personal use only ▪ Major disease areas: Cancer, atherosclerosis and infectious diseases Meeting Clinical ▪ Advancing Photosoft™ technology – novel PDT photosensitiser INV043 Needs ▪ Collaboration with world-class expertise (Hud
Slide 5: The Photosoft Advantage: A Novel Cancer Treatment
THE PHOTOSOFTTM ADVANTAGE A NOVEL CANCER TREATMENT For personal use only NGPDT (Next-Gen PDT) is a ground-breaking NGPDT is a minimally invasive modality for technology that overcomes many of the treating cancer that specifically identifies and shortcomings of early PDT technologies and destroys can
Slide 6: Lead Drug Candidate INV043: Pathway to a US$271B Market Opportunity
LEAD DRUG CANDIDATE INV043 PATHWAY TO A US$271B MARKET OPPORTUNITY1 For personal use only Proof-of-Concept studies of lead candidate INV043 has been shown to: Selectively absorbed by cancer cells and not healthy tissue Invion is leading the Effective in regressing multiple types of cancer in vivo gl
Slide 7: Key Partnerships: World-Leading Institutions
KEY PARTNERSHIPS WORLD-LEADING INSTITUTIONS For personal use only • Global bioscience medical research institute • World-class institute that combines its premier • Over 400 scientists focused on ground-breaking cancer research capability with its ability to discoveries addressing complex problems i
Slide 8: Findings: Proof-of-Concept Studies on INV043 undertaken by Hudson Institute
For personal use only Findings Proof-of-Concept Studies on INV043 undertaken by Hudson Institute
Slide 9: Improved API: INV043 Key Characteristics
IMPROVED API: INV043 KEY CHARACTERISTICS For personal use only Active against multiple cancers Highly potent and selective A. A. INV043 INV034 activityMultiple Activity INV043 Activity against multiple Against Against cancer cell types B. INV04 MultipleCancer CancerCell Types Cell Types 100 100 100
Slide 10: Desirable Therapeutic Profile
DESIRABLE THERAPEUTIC PROFILE MULTIPLE CANCERS, HIGH POTENCY, LOW NON-SPECIFIC TOXICITY For personal use only INV043 phototoxicity was evaluated in multiple human cancer cell types including ovarian, colorectal, kidney, lung, triple negative breast and T-cell lymphoma. Assays were performed in vitro
Slide 11: In Vivo Proof of Concept: Tumour Localisation
IN VIVO PROOF OF CONCEPT: TUMOUR LOCALISATION SELECTIVITY IN PRIMARY AND METASTATIC TUMOURS, NON-TOXIC For personal use only Localisation in vivo was monitored over time using the intrinsic fluorescence of INV043 under blue light. • INV043 localises to tumour: Intratumoral (IT - for subcutaneous tum
Slide 12: In Vivo Proof of Concept: Tumour Regression
IN VIVO PROOF OF CONCEPT: TUMOUR REGRESSION SIGNIFICANT REGRESSION ON MULTIPLE TUMOUR TYPES For personal use only INV043 was used to treat implanted T-cell lymphoma, breast and pancreatic cancers in vivo (n=4-8/group). Low dose INV043 (0.1mg/kg) was administered by IT injection and laser light (220J
Slide 13: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only Treatment with established tumours (INV043 with light) • INV043 was injected intratumorally (0.1mg/kg) • 16 hours later, illuminated with red light • No anaesthesia required, no adverse effects obse
Slide 14: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only • Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies • Proof of Concept (PoC) pilot showed complete regression of TNBC in vivo following INV043 treatment
Slide 15: Proof of Concept: Immune Checkpoint Inhibitors Combination Therapy
PROOF OF CONCEPT: IMMUNE CHECKPOINT INHIBITORS (ICI) COMBINATION THERAPY FOR A US$140B MARKET1 (BY 2030) For personal use only • Immune checkpoint inhibitors are widely used for the treatment of lung cancer and melanoma. However, ICI treatments are typically only effective on a small proportion of p
Slide 16: The Way Forward: Multiple Catalysts and Milestones
THE WAY FORWARD MULTIPLE CATALYSTS AND MILESTONES For personal use only Australia • Proof of Concept (PoC) Building on in vivo work further demonstrating both safety and efficacy profiles • Pre-clinical Preparations: Building foundations for clinical trials in multiple indications and internationall
Slide 17: Management Team
MANAGEMENT TEAM THE RIGHT EXPERTISE FOR SUCCESS For personal use only THIAN CHEW MELANIE LEYDIN EXECUTIVE CHAIRMAN & CEO CFO • Managing Partner, Polar Ventures • 25+ years in accounting profession • Executive Director, Goldman Sachs • Partner, Vistra • Director, KPMG Consulting, Senior Manager KPMG
Slide 18: Summary
SUMMARY For personal use only Promising Early Results: Total tumour Well Funded: Cancer program fully regression, immune response, potential funded & AID partially funded by ICI combination therapies RMWC World-Leading Partnerships: Multiple Growth Options: Large Collaboration with internationally a
Slide 19: Market Overview
12 Months Share Price* MARKET OVERVIEW $0.01 For personal use only (as of 15 Jun 2022) Market Cap A$64.2m Clinical-stage life sciences TOP 10 SHAREHOLDERS* %IC company developing the Focus PhotosoftTM technology as Polar Ventures Limited 8.50 a treatment for a range of NGPDT Greater China Limited 8.
Slide 20: For personal use only
For personal use only